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Abstract Lipoprotein (a) (Lp(a)) is a modified low-den-
sity lipoprotein (LDL) particle with an additional specific
apolipoprotein (a), covalently attached to apolipoprotein
B-100 of LDL by a single thioester bond. Increased plasma
Lp(a) level is a genetically determined, independent, causal
risk factor for cardiovascular disease.
The precise quantification of Lp(a) in plasma is still
hampered by mass-sensitive assays, large particle variation,
poor standardization and lack of assay comparability.
The physiological functions of Lp(a) include wound
healing, promoting tissue repair and vascular remodeling.
Similarly to other lipoproteins, Lp(a) is also susceptible for
oxidative modifications, leading to extensive formation of
pro-inflammatory and pro-atherogenic oxidized phospho-
lipids, oxysterols, oxidized lipid-protein adducts in Lp(a)
particles, that perpetuate atherosclerotic lesion progression
and intima-media thickening through induction of M1-
macrophages, inflammation, autoimmunity and apoptosis.
The oxidation-specific epitopes of modified lipoproteins are
major targets of pre-immune, natural IgM antibodies, that
may attenuate the pro-inflammatory and pro-atherogenic
effects of Lp(a).
Although the data are still insufficient, recent studies
suggest a potential anti-neoplastic role of Lp(a).




1 Institute for Clinical Chemistry and Laboratory
Medicine, University Hospital of Regensburg,
Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany
Keywords Lipoprotein(a) · Pathophysiology ·
Atherogenesis · Inflammation · Tumor-growth
Introduction
Lipoprotein(a) (Lp(a)) is one of the most enigmatic lipopro-
tein particles in humans and its increased plasma concentra-
tion is an independent predictor for atherosclerotic cardio-
vascular disease (CVD) and peripheral arterial disease ([1]
and references therein). Mendelian randomization studies
have recently provided convincing evidence that Lp(a) is
a genetically determined causal risk factor for myocardial
infarction, atherosclerotic stenosis and aortic valve stenosis
(reviewed in [2]). Other disease groups, like heart failure
and venous thromboembolism, are under current evaluation
[2]. Clinical investigation of Lp(a) is largely hampered by
the fact that Lp(a)-hyperlipidemia (Lp(a)-HLP) frequently
co-incides with other genetic factors for hyperlipidemia and
risk of CVD, such as familial hypercholesterolemia (FH) or
apolipoprotein E4-allele [3, 4].
Despite extensive research, the underlying mechanisms
by which Lp(a) mediates atherogenesis and inflammation,
and how Lp(a) contributes to vascular diseases, are still
incompletely understood.
Structure and genetics of Lp(a)
The Lp(a) is largely similar to the low density lipoprotein
(LDL) particle, containing one molecule of apolipoprotein
B-100 (apoB-100) around a lipid core of cholesteryl es-
ters, triacylglycerols, diverse phospholipids and unesterified
cholesterol. In addition, a highly glycosylated, hydrophilic
apolipoprotein (a) (apo(a)) is unique for Lp(a), distinguish-
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ing Lp(a) from LDL (reviewed in [5]). Apo(a) shows a high
amino acid sequence homology to the serine protease plas-
minogen, and consists of a carboxy-terminal, enzymatically
inactive, protease-like domain followed by a kringle-V do-
main and a variable kringle-IV (K-IV) domain ([5] and
references therein). The K-IV domain of apo(a) appears as
10 diverse types (T1-T10) [5]. While T1 and T3-T10 are
present as a single copy in one apo(a) molecule, the number
of T2 varies between 3 and 43 ([5] and references therein).
As a consequence, the different repeats of K-IVT2 in apo(a)
account for the high size polymorphism of this apolipopro-
tein [5]. There is an inverse relationship between the num-
ber of K-IVT2 repeats of apo(a) and the level of Lp(a) in
plasma ([1, 5] and references therein). The size length of
apo(a) largely determines its rate of hepatic synthesis and
secretion, and also the mass of circulating Lp(a) [6].
Apo(a) is covalently linked to apoB-100 by a single
disulfide bond on K-IVT9, in close proximity to the LDL
receptor binding site of apoB-100 (reviewed in [1]). The
characteristic ‘lysine binding site’ (LBS) of apo(a), which
is critically important for many cellular effects and athero-
genic potential of Lp(a), is located on K-IVT10 [1].
Apo(a) is encoded by two alleles of the LPA gene (chro-
mosome 6q26), and several genetic LPA-variants have been
published, including variations in the K-IV repeats, diverse
single nucleotide polymorphisms (SNPs) and other pro-
moter variants in the LPA gene region [1, 2, 5]. The plasma
concentrations of Lp(a) show significant diversity in ethni-
cal groups (e. g. Caucasians have lower plasma Lp(a) lev-
els than African-Americans), and in individuals carrying
apo(a) even of the same size polymorphism [7, 8]. Fur-
thermore, elderly individuals (above 75 yrs) tend to show
marginally, but not significantly, elevated plasma levels of
Lp(a) as compared to the general population under 75 yrs
[9].
Measurement of Lp(a) in plasma
Although Lp(a) quantification in human plasma (or serum)
belongs to standard assays in most clinical laboratories, the
precise quantitative analysis of Lp(a) is still a challenge
with many pitfalls: (i) Lp(a) particles are present in differ-
ent molecular masses, depending on the differences in iso-
form size of apo(a), as it varies between 275 and 800 kDa
[10, 11]. Novel commercial Lp(a) assays are now avail-
able that are insensitive to the variability in Lp(a) mass
isoforms [5]. Lp(a) mass refers to the entire mass of the
whole particle, including lipids, proteins and carbohydrates
[5, 12]. In addition to the apo(a) isoform mass, however,
there is also a large variability in the lipid mass within Lp(a)
particles [12]. Thus, availability of particle-based, mass-in-
sensitive Lp(a) assays is of great importance. In a recent
paper Guadagno and co-workers presented the validation
data of an Lp(a) particle concentration assay by quantitative
lipoprotein immunofixation electrophoresis, showing preci-
sion and linearity across a 16-fold range, which is suitable
for use in clinical laboratories [13]. (ii) Most Lp(a) assays
are based on immunological methods (e. g. immunoneph-
elometry, immunoturbidimetry, ELISA) using antibodies
against apo(a). In contrast to previous immunoassays with
antibodies binding to K-IVT2, antibodies in more recent as-
says should recognize K-IVT9, since this binding site is more
stable than K-IVT2 [10]. (iii) Apo(a) isoforms, selected for
previous immunological Lp(a) assay calibrators, are with
small apo(a) sizes, thus leading to a consequent overesti-
mation of Lp(a) levels in all clinical samples, in which the
apo(a) isoforms are larger than in the calibrator [5]. The
approaches for Lp(a) immunoassay optimization by imple-
mentation of international reference reagents have partially
solved this analytical problem, and some recently available
commercial Lp(a) assays provide acceptable robustness and
analytical precision ([5] and references therein). In addition,
the simultaneous quantitation and size characterization of
apo(a) by ultra-performance liquid chromatography/mass
spectrometry was also reported [14]. (iv) Lp(a) levels, deter-
mined by optimized apo(a) isoform dependent assays (see
previous point), are delivered in nmol/L [5], and this form
should be preferred in current studies. However, other Lp(a)
assays may report their results in mg/L. No factor should be
used for conversion of Lp(a) concentrations from mg/L to
nmol/L, or vice versa, as this may lead to misinterpretation
of data and confusion [5]. (v) Currently, there is no gen-
erally accepted patient threshold for elevated plasma Lp(a)
and the prevalence of Lp(a)-HLP in the general population
is not yet defined. In a very recent study an attempt has
been made to assess the distribution of plasma Lp(a) in
a large US-cohort, and the data may influence consensus
documents, guidelines and therapeutic cut-offs for Lp(a)-
mediated risk for CVD in the future [15].
Function of Lp(a)
The physiological role of Lp(a) in human is still not fully
elucidated, and individuals with extremely low levels of
plasma Lp(a) present no disease or deficiency syndromes
[6]. Earlier works agree that Lp(a) accelerates wound heal-
ing and tissue repair, and therefore Lp(a) provided an evo-
lutionary advantage to humans [6, 16]. Indeed, Lp(a) accu-
mulates in endothelial injuries, binds to several components
of the vessel wall and the sub-endothelial matrix, stimulates
chemotactic activation of monocytes/macrophages, modu-
lates angiogenesis, and all these effects are mediated by
apo(a) [6, 16].
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Effects of Lp(a) on vascular endothelial cells
In previous years Koschinsky and co-workers have demon-
strated in consecutive papers how apo(a) modifies the cellu-
lar function of cultured vascular endothelial cells: (i) Apo(a)
stimulates migration and proliferation of HUVECs (human
umbilical-vein endothelial cells) through a mechanism in-
volving CD51/CD61 (integrin αVβ3), Src and MAP (mito-
gen-activated protein) kinases, including ERK (extracellu-
lar-signal-regulated kinase), p38 and JNK (c-Jun N-termi-
nal kinase) [17]. (ii) Apo(a) induces a RhoA/Rho-kinase
signalling, leading to formation of stress fibers, endothe-
lial contraction and vascular permeability [18]. (iii) Apo(a)
disrupts VE-cadherin/β-catenin complexes via a Src-depen-
dent mechanism, which leads to decreased phosphorylation
of β-catenin, parallel with increased phosphorylation of Akt
and glycogen synthase kinase-3β. This phosphorylation-
shift leads to an increased nuclear translocation of β-catenin
and subsequent induction of cyclooxygenase-2 (COX-2)
gene expression, thus mediating enhanced prostaglandin
E2 (PGE2) formation [19]. (iv) Apo(a) increases the gene
expression of certain adhesion molecules, including CD54
(ICAM-1) and CD62E (E-selectin) by a yet unclear mecha-
nism ([20] and references therein). (v) Apo(a) inhibits peri-
cellular activation of plasminogen by a mechanism involv-
ing urokinase-type plasminogen activator (uPA) and CD87
(uPA-receptor), resulting in decreased myoepithelial orga-
nization and formation of new vascular tubes ([20] and ref-
erences therein).
Effects of Lp(a) on smooth muscle cells
In addition to endothelial cells, Lp(a) also influences the
function of smooth muscle cells (SMCs) through apo(a):
(i) Apo(a) induces a concentration-dependent chemorepul-
sion of SMCs in migration assays via a mechanism involv-
ing CD51/CD61 and RhoA/Rho-kinase, but not transform-
ing growth factor-β (TGFβ) [21]. (ii) Lp(a) dampens the
activity of TGFβ in SMCs, and the factors contributing to
this effect have yet to be identified [16].
Effects of Lp(a) on monocytes/macrophages
It has been demonstrated that Lp(a) promotes the differ-
entiation of pro-inflammatory, M1-type macrophages, that
secrete a set of pro-inflammatory cytokines (e. g. inter-
leukin (IL)-1β, IL-6, IL-8, tumor necrosis factor (TNF)-
α) and chemokines, like ‘interferon-gamma-induced pro-
tein-10’ (IP10, CXCL10) and ‘Regulated on Activation,
Normal T-cell Expressed and Secreted’ (RANTES, CCL5),
leading to activation of T-helper-1 (Th1) cells and natural
killer (NK) cells [22–25]. The chemokines CXCL10 and
RANTES are accompanied with inhibition of angiogenesis,
which may affect function of vasa vasorum [25].
Taken together, the above mentioned cellular effects of
Lp(a) underline its function as potent modulator of tissue
remodelling, nevertheless the same mechanisms also con-
tribute to sustained plaque development in atherosclerosis.
Lp(a) and inflammation and atherogenesis
Similarly to other lipoproteins Lp(a) is also susceptible to
oxidative modifications, leading to formation of pro-inflam-
matory and pro-atherogenic oxidized phospholipids, oxys-
terols, oxidized lipid-protein adducts, termed ‘oxidation-
specific epitopes’ (OSEs), produced in response to reac-
tive oxygen species (ROS) ([1, 26] and references therein).
Different OSEs are present on Lp(a) as ‘danger-associ-
ated molecular patterns’ (DAMPs) that perpetuate local in-
flammation, apoptosis and tissue disintegration, and they
are recognized by a set of pattern-recognition receptors
(PRRs) that trigger innate immunity [1, 26]. The most
important Lp(a)-associated DAMPs, PRRs and their ma-
jor downstream signalling mechanisms are summarized in
Fig. 1.
By using OSE-specific monoclonal antibodies (particu-
larly T15/E06 IgM), recognizing oxidatively modified but
not native phospholipids, Witztum, Tsimikas and colleagues
found correlations between plasma levels of oxidized phos-
pholipids and plasma Lp(a), apo(a) size polymorphism,
CVD and progression of aortic valve stenosis [1, 26, 27].
Furthermore, by the E06 antibody they were able to block
the recognition and uptake of oxidized phospholipids and
apoptotic cells by DAMPs, and thus reduce the progression
of CVD in atherosclerosis-susceptible mice (reviewed in [1,
26]).
In a recent study Scipione et al. have shown that re-
combinant apo(a) with 17 subdomains within K-IV induces
a dose-dependent increase in expression of IL-8 (mRNA
and protein) in macrophage cell lines via CD36 and Toll-
like receptor-2 (TLR2)-mediated signalling involving MAP
kinases, JNK and ERK [28]. Furthermore, this stimulatory
effect was linked to the LBS in K-IVT10 of apo(a), since it
was unaffected by trypsin-treatment, but dampened by mu-
tation of the LBS resulting in the loss of oxidized phospho-
lipid on apo(a) [28]. Enzymatic removal of oxidized phos-
pholipid from apo(a) also blunted the IL-8 inducing effect
of apo(a), thus verifying the LBS as OSE [28]. Consistent
with these results the same group also showed increased
monocyte trafficking to the arterial wall in subjects with
Lp(a)-HLP, as compared to probands with normal Lp(a)
levels, using in vivo high resolution imaging techniques
[29]. In addition, a parallel ex vivo approach demonstrated
the pro-inflammatory activation of monocytes in Lp(a)-HLP
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Fig. 1 Schematic figure de-
picting major charge-/motif- and
opsonin receptors involved in
signaling and clearance of oxi-
dized phospholipids, lysophos-





























































































[29]. Furthermore, in vitro experiments revealed that Lp(a)
from Lp(a)-HLP patients contained oxidized phospholipids,
and this modified Lp(a) augmented the pro-inflammatory
response of monocytes derived from healthy control sub-
jects [29]. The effect was markedly attenuated by inacti-
vating oxidized phospholipids on Lp(a) or removing them
from apo(a) [29]. In this scenario not apo(a) itself, but rather
OSEs in apo(a) are responsible for the (patho)physiological
function(s) of Lp(a), and the LBS is one of the important
OSEs in Lp(a).
In addition, modified Lp(a) binds and carries pro-inflam-
matory molecules such as the monocyte chemoattractant
protein-1 (MCP-1/CCL2), a major chemokine inducing and
maintaining vascular inflammation, and oxidized phospho-
lipids of modified Lp(a) were shown to be major determi-
nants for MCP-1 binding [30].
Taken together, Lp(a) promotes inflammation and
atherosclerosis by multiple mechanisms, and OSEs of
apo(a) are critically involved in the pathogenesis of Lp(a)
(Fig. 1).
Association studies have shown that plasma levels of
IgM antibodies against OSEs are inversely correlated with
CVD (reviewed in [31]), and OSEs are major targets
of pre-immune, natural IgM antibodies in humans and
mice [32]. Approximately 30% of all natural IgM an-
tibodies, recognizing diverse OSEs, were found to bind
to atherosclerotic lesions and apoptotic cells in a mouse
model [32]. Furthermore, genetic deficiency of secreted
IgM (sIgM-/-) in mice dramatically accelerates atheroscle-
rosis on the LDL receptor deficient (Ldlr-/-), atherosclero-
sis-susceptible mouse background, parallel with increased
plasma IgE levels and perivascular accumulation of mast
cells and neutrophils within the plaques [33]. In addition,
the OSE-specific T15/E06 IgM blocks the recognition
of the oxidized phospholipid POVPC (1-palmitoyl-2-(5-
oxovaleroyl)-sn-glycero-3-phosphorylcholine) by the scav-
enger receptor CD36 [34], and the IL-6 secretion, induced
by oxPAPC (oxidized 1-palmitoyl-2-arachidonoyl-sn-glyc-
ero-3-phosphocholine) in macrophages [35]. The OSE-
specific natural NA17 IgM, recognizing a malondialdehyde
(MDA) epitope, binds apoptotic cells and promotes their
clearance by macrophages [32]. These findings clearly
demonstrate the atheroprotective role of natural, OSE-
specific IgM antibodies [31].
Autoantibodies against modified LDL were demon-
strated in human plasma, and increased levels of these
autoantibodies correlated with severe atherosclerosis [36].
Interestingly, elevated levels of IgM autoantibodies against
OSE-specific apoB-immune complexes reduced the cardio-
vascular risk of Lp(a) in a recent epidemiological study
[37]. In previous works Romero et al. reported autoantibod-
ies against MDA-modified Lp(a) in plasma of patients with
antiphospholipid syndrome (APS) [38] and systemic lupus
erythematosus (SLE) [39], thus linking Lp(a) to autoim-
munity. Indeed, similarly to the formation of OSE-specific
IgM autoantibodies against modified LDL, autoantibodies
against oxidatively modified epitopes of Lp(a) can also be
developed, and these autoantibodies may attenuate the pro-
inflammatory and pro-atherogenic signalling of Lp(a).
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Lp(a) and malignancies
It was demonstrated nearly two decades ago that angio-
statin, a cancer-mediated proteolytic fragment of plasmino-
gen, is able to inhibit metastasis and neovascularization of
tumors [40]. Based on the high grade of homology between
plasminogen and apo(a), the potential anti-neoplastic role
of Lp(a) was always postulated, but convincing evidence
has not yet been demonstrated ([6] and references therein).
Taking into account that Lp(a) shows growth-factor-
like properties, including stimulation of angiogenesis, one
would rather expect that Lp(a) promotes tumor growth,
as malignant cells would likely benefit from neovascu-
larization. Regarding that Lp(a)-HLP is associated with
increased amounts of oxidized phospholipids and OSEs, it
is tempting to speculate that autoantibodies against oxidized
phospholipids develop in Lp(a)-HLP, and these antibodies
may antagonize some OSE-associated pro-inflammatory
and angiogenic events. Finally, the dampened angiogenic
signalling may thus reduce vascularization of tumors.
Previous studies in animal models suggest that the prote-
olytic break-down fragments of apo(a) are responsible for
the anti-angiogenic and anti-neoplastic function of Lp(a)
(reviewed in [41]). In a very recent study Lp(a) and vita-
min C were found to impair development of breast cancer
in a mouse model, transgenic for human Lp(a) and deficient
in endogenous vitamin C production [42].
Despite promising in vivo and in vitro results epidemio-
logical studies have failed to clearly link Lp(a) with tumor
protection so far. In a recent work Sawabe and colleagues
reported a link between low Lp(a) levels and all-cause and
cancer death [43]. The same group found Lp(a)-HLP as
a significant risk factor for any origins of cancer [44]. Fur-
thermore, increased Lp(a) levels in plasma is commonly
reported in tumor patients in comparison to controls, irre-
spective of source of the tumor [6, 41, 45, 46].
Taken together, the current knowledge about the anti-
neoplastic function is insufficient and further investigations
are required to clarify this important question.
Conclusion
In recent years several important consecutive data have
been presented showing cellular and molecular mechanisms
of Lp(a) action. Convincing evidence has been presented
that the pro-inflammatory and pro-atherosclerotic effects of
Lp(a) are largely attributed to different OSEs present in
Lp(a) particles.
Different OSEs are major targets of pre-immune, natural
IgM antibodies, and autoantibodies against oxidized phos-
pholipids may develop in Lp(a)-HLP, thus antagonizing the
detrimental effects of Lp(a).
The anti-neoplastic effect of Lp(a) is not convincingly
demonstrated, and further investigations are necessary to
clarify this question.
Despite emerging data from clinical and experimental
studies our current knowledge about the impact of Lp(a)-
HLP in diverse pathologies is still rudimentary. For fur-
ther studies establishment of novel biomarkers and particle-
based, mass-insensitive assays for quantification of Lp(a)
are essentially required.
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